Rifaquizinone

N/A

Report date: 2026/03/04 20:01:44
NMEQIDP

Base Information

Drug NameRifaquizinone
Drug Alias NameCBR-2092TNP-2092TNP-2092 IVTNP-2092 PO
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Quinolone antibiotics
Mechanisms of ActionBacterial DNA gyrase inhibitorsBacterial DNA-directed RNA polymerase inhibitorsTopoisomerase IV inhibitors
TargetsBacterial DNA-directed RNA polymeraseBacterial DNA gyraseTopoisomerase IV
Therapy Area/IndicationsHelicobacter pylori infectionAcute bacterial skin and skin structure infectionsHyperammonemia +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCumbre Pharmaceuticals
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesDanuo Pharmaceutical (Zhongshan) Co LtdTenNor Therapeutics IncThe University Of Iowa +[5] 
Inactive CompaniesN/A
Active IndicationsAcute bacterial skin and skin structure infectionsHyperammonemiaDiabetic Foot +[7] 
Inactive IndicationsHelicobacter pylori infectionDuodenal UlcerGram-Positive Bacterial Infections +[4] 

Other Information

ATC CodeN/A
Related LinksN/A